Behavioral and psychological symptoms of dementia: Part II-treatment

Clinical Geriatrics

Volumn 19, Issue 6, 2011, Pages

  Tampi, Rajesh R ^a,b   Williamson, Deena ^c   Muralee, Sunanda ^a   Mittal, Vikrant ^d   McEnerney, Nicole ^b   Thomas, Jennifer ^b   Cash, Mary ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Masonicare   (United States)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^d BJC HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; DONEPEZIL; FLUOXETINE; GALANTAMINE; HALOPERIDOL; MEMANTINE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TRAZODONE; VALPROATE SEMISODIUM;

AGITATION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; CONFUSION; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERAMMONEMIA; LIVER DYSFUNCTION; METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOEDUCATION; QT PROLONGATION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 80051895713     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hemels ME, Lanctôt KL, Iskedjian M, Einarson TR. Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging. 2001;18(7):527-550. (Pubitemid 32664727)
2. Tampi RR, Williamson D, Muralee S, et al. Behavioral and psychological symptoms of dementia: part I-epidemiology, neurobiology, heritability, and evaluation. Clinical Geriatrics. 2011;19(5):41-46.
3. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-255.
4. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry. 2005;20(4):301-314. (Pubitemid 40590491)
5. Livingston G, Johnston K, Katona C, et al; Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996-2021. (Pubitemid 41598254)
6. Hepburn KW, Tornatore J, Center B, et al. Dementia family caregiver training: affecting beliefs about caregiving and caregiver outcomes. J Am Geriatr Soc. 2001;49(4):450-457. (Pubitemid 32390879)
7. Marriott A, Donaldson C, Tarrier N, Burns A. Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. Br J Psychiatry. 2000;176(6):557-562. (Pubitemid 30353657)
8. Ostwald SK, Hepburn KW, Caron W, Burns T, Mantell R. Reducing caregiver burden: a randomized psychoeducational intervention for caregivers of persons with dementia. Gerontologist. 1999;39(3):299-309. (Pubitemid 29302479)
9. Brodaty H, McGilchrist C, Harris L, Peters KE. Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. Arch Neurol. 1993;50(6):643-650. (Pubitemid 23165595)
10. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608. (Pubitemid 40171242)
11. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
12. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsy-chotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
13. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness and safety of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538. (Pubitemid 44547805)
14. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465. (Pubitemid 34184743)
15. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169-183.
16. Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev. 2004;(2):CD003945.
17. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54-61. (Pubitemid 28037549)
18. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9(4):400-405. (Pubitemid 33015127)
19. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293-308. (Pubitemid 351230232)
20. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2004;(4):CD001747.
21. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210-216. (Pubitemid 36068709)
22. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459-464. (Pubitemid 40716339)
23. Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32-38.
24. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4): 494-504. (Pubitemid 34260999)
25. Miller LJ. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother. 2001;35(4):427-431. (Pubitemid 32260208)
26. Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. Drugs Aging. 2008;25(3):187-196. (Pubitemid 351363751)
27. Health Canada. Updated safety information for Risperdal* (risperidone) in elderly dementia patients, announced in Canada by Janssen-Ortho Inc. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/-2002/ risperdal-2-pa-ap-eng.php. Accessed May 29, 2011.
28. U.S. Food and Drug Administration. Risperdal (risperidone) dear healthcare professional letter Apr 2003. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm168933.htm. Accessed May 29, 2011.
29. The European Agency for the Evaluation of Medicinal Products. EMEA public statement on the safety of olanzapine (Zyprexa, Zyprexa Velotab). http://www.bfarm.de/cae/servlet/contentblob/1020888/publicationFile/79624/ emea-zyprexa-st.pdf. Accessed May 29, 2011.
30. R Medicines and Healthcare Products Regulatory Agency. Atypical antipsychotic drugs and stroke. http://www.mhra.gov.uk/Safetyinformation/ Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON1004298. Accessed May 29, 2011.
31. U.S. Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformation forHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm. Accessed May 29, 2011.
32. U.S. Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafety informationforpatientsandproviders/ucm124830.htm. Accessed May 29, 2011.
33. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103. (Pubitemid 40321762)
34. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005; 330(7489):445-448. (Pubitemid 40314208)
35. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66(9):1090-1096. (Pubitemid 41442273)
36. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. (Pubitemid 41464695)
37. Gill SS, Bronskill SE, Normand ST, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786. (Pubitemid 351650498)
38. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients [published correction appears in CMAJ. 2007;176(11):1613]. (Pubitemid 46868615)
39. CMAJ. 2007;176(5):627-632.
40. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Review: risk of cerebrovascu-lar adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(1):10-28.
41. EQUETROTM (carbamazepine) extended-release capsules Rx only. http://www.access data.fda.gov/drugsatfda-docs/label/2006/021710s003lbl.pdf. Accessed June 3, 2011.
42. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
43. Williams MM, Roe CM, Morris JC. Stability of the Clinical Dementia Rating, 1979-2007. Arch Neurol. 2009;66(6):773-777.
44. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4 Suppl 1:55-69.
45. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-1139. (Pubitemid 12051593)
46. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
47. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-S56.